The Merck and Ridgeback's Investigational Oral Antiviral pill- Molnupiravir will soon be available in the medicinal market in Assam.
On November 18, it has been approved by the panel of the Indian Drug Controller. Sold under the brand name, Lagevrio is an anti-viral medication that inhabits the replica of certain RNA viruses.
So far vaccination has been the only way of treating Coronavirus but now Molnupiravir is raising hopes that Covid can be cured. It is the first potential prescription pill for Covid-19.
It is said to have a particular benefit to unvaccinated people with underlying health issues. In trials, the conclusion was made that this drug cut hospitalization and death by half. Researchers at the 'Centre for Disease Control & Prevention' say that this pill is even highly effective against the delta variant, gamma and mu mutation.
Researchers at the 'Centre for Disease Control & Prevention' say that this pill is even highly effective against the delta variant, gamma and mu mutation.Virologist Dr. Gangandeep Kang says that this particular medicine should be given to patients as soon as they start showing symptoms. It is advisable to take this pill within 5 days of visualizing the symptoms.
The trial of this medicine was carried out among the common people in the UK and the results were that most of the people did not require any kind of hospitalization nor had any severity in the illness.
The medicine was requested by 8 pharmaceutical companies from India. Reduced the risk of hospitalization or death by approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.
The drug did not show any kind of side-effect on the volunteers it was tried on. As it works by disrupting how the coronavirus replicates RNA, there could be a concern of a similar effect on human DNA or RNA.
In the future, a concern may be that this drug would interfere with RNA replication needed for fetus development and cause child defects. This pill is recommended for high-risk adults.